Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
SWOG Cancer Research Network
Academic and Community Cancer Research United
University of Giessen
National Institutes of Health Clinical Center (CC)
Fondazione Italiana Linfomi - ETS
Novartis
French Innovative Leukemia Organisation
Nanfang Hospital, Southern Medical University
University of Minnesota